Evidence map›Paper›PMID 40948582›Full record

ArticleMaterials today. Bio2025

Synergistic HER2-scFv mediated immunotherapy with targeted gemcitabine delivery harnessing biomimetic composite nanoparticles for enhanced metastatic tumor therapy.

Xinan Wang, Wenhui Chu, Fuyu Du, Hongyu Fan, Zixuan Ye, Yaru Xue, Xianghan Zhang, Peng Yang, Yuqiong Xia, Zhihui Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinan WangSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Wenhui ChuSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Fuyu DuSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Hongyu FanSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Zixuan YeSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Yaru XueSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Xianghan ZhangSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Peng YangSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Yuqiong XiaSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.
Zhihui ChenDepartment of Gastrointestinal Surgery Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China.
Pengbo NingSchool of Life Science and Technology, Xidian University, Xi'an, 710071, Shaanxi, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic breast cancer poses a formidable challenge to global female health and public hygiene. Patients with HER2

Indexed as

Anti-HER2Biomimetic nanoplatformCombined therapyMacrophage membrane camouflageMetastatic tumors

Identifiers

PMID40948582
PMCPMC12423602

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.